A new label for the antidepressant, known generically as duloxetine, also includes reports of hepatitis, jaundice and other liver-related problems in patients using the drug, the U.S. Food and Drug Administration says on its Web site.
"Some of these reports indicate that patients with preexisting liver disease who take duloxetine may have an increased risk for further liver damage," the company said in a letter issued to doctors.
A spokeswoman for the drugmaker could not be immediately reached for comment.
